New transplant approach aims to tame bone marrow failure
NCT ID NCT06412497
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a bone marrow transplant using lower doses of chemotherapy and radiation to prepare the body, along with a drug called cyclophosphamide after transplant to prevent graft-versus-host disease. It enrolls 60 people with severe aplastic anemia or related bone marrow failure conditions. The goal is to see if this approach reduces serious complications while still helping the body produce healthy blood cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- hematopoietic cell transplant with reduced intensity conditioning and post-transplant cyclophosphamide
- What this could lead to
- If successful, this could offer a safer transplant option for people with severe bone marrow failure, reducing serious side effects like graft-versus-host disease.
- What could go wrong
- This is an early phase 2 trial with only 60 participants, so results may not apply to everyone. The transplant still carries risks of infection, organ damage, and graft failure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACQUIRED AMEGAKARYOCYTIC THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Minnesota Masonic Cancer Center
RECRUITINGMinneapolis, Minnesota, 55455, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A pill that could replace infusions for a rare blood disease?
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Every-8-Week shot could simplify PNH treatment
- Half-Matched stem cell transplant offers hope for children with blood disorders
- Real-World test: can a targeted drug keep PNH in check for years?
- New transplant method aims to reduce complications in bone marrow failure patients